Tag Archives: Gilead

AMCP Talk Pricing of Specialty Pharma Spurred by Sovaldi

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”
Posted in healthcare, Market Access, pricing | Also tagged , , , , , , | Leave a comment

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , , , , , | Leave a comment

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Posted in healthcare, pricing, Strategy | Also tagged , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Also tagged , , , , , | 1 Comment

Sovaldi “Biggest Selling Drug” by 2020

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate. “Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” […]
Posted in Europe, Gene therapy, Global, Sales, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta